Latest Breaking News On - ஆர்த்தி மருந்துகள் - Page 1 : comparemela.com

Glenmark manufacturing plant at Dahej, Gujarat; Image courtesy: Glenmark Synopsis The company’s performance has been robust 16% CAGR in revenue and 17% CAGR in Ebitda over the last three years, and an Ebitda margin of over 30%. Besides, it has fared well in the critical parameter of quality compliance. It is now looking to expand its manufacturing capacity, product portfolio, and geographical presence, but can it continue its run? Active pharmaceutical ingredients (APIs) are the backbone of pharma industry. When the pandemic struck, cracks in the pharma supply chain were exposed, especially the high dependence on China for APIs and other key raw materials. This brought the not-so-glamorous API sector into the limelight. Over the last one year, API makers in India like Divi’s Laboratories, Laurus Labs, Aarti Drugs, Granules India, and Solara Active Pharma Sciences have not

Solara active pharma sciencesLaurus labsAarti drugsGranules indiaசோலாரா செயலில் பார்மா அறிவியல்லாரஸ் ஆய்வகங்கள்ஆர்த்தி மருந்துகள்துகள்கள் இந்தியா